Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF-00299804 In Patients With Advanced Solid Tumors

Pfizer121 enrolled

Overview

The primary purpose of this study is to study the side effects of PF-00299804 and determine the highest dose that can be safely administered in patients with advanced cancer.

Study Type

INTERVENTIONAL

Purpose

TREATMENT

Masking

NONE

Enrollment

121

Conditions

Neoplasms

Interventions

PF-00299804DRUG

investigational drug by oral route (escalating doses depending on safety) administered until progression

Eligibility

Sex: ALLMin age: 18 YearsMax age: 99 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Malignant solid tumor for which there is no currently approved treatment * Adequate bone marrow, liver, cardiac, and kidney function Exclusion Criteria: * Cardiac disease * Anticancer therapy within 4-6 weeks (depending on therapy) * Pregnant or breast-feeding

Locations (9)

Ronald Reagan UCLA Medical Center

Los Angeles, California, United States

UCLA Hematology/Oncology

Los Angeles, California, United States

UCLA Oncology Center

Los Angeles, California, United States

Outcomes

Primary Outcomes

Safety

Time frame: 6 months

Secondary Outcomes

Pharmacokinetics

Time frame: 6 months

Pharmacodynamics

Time frame: 6 months

Efficacy

Time frame: 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.